LY2510924 is primarily used in the field of oncology research, particularly in studies focused on cancer treatment. It functions as a CXCR4 antagonist, which means it inhibits the activity of the CXCR4 receptor. This receptor is known to play a significant role in tumor growth, metastasis, and angiogenesis. By blocking CXCR4, LY2510924 helps to disrupt the signaling pathways that cancer cells use to proliferate and spread to other parts of the body. Researchers are investigating its potential to enhance the efficacy of other cancer therapies, such as chemotherapy and immunotherapy, by preventing cancer cells from evading treatment and establishing new tumors. Additionally, it is being explored for its role in mobilizing stem cells from the bone marrow, which can be beneficial in certain types of stem cell transplantation procedures.